Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Machado ‘presented’ her Nobel Peace Prize medal to Trump - 2High Court weighs Assenheim appeal over release of Feldstein interview raw footage
- 3Vote In favor of Your Favored Treat
- 4IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- 5Really focusing on Succulents: Tips and Procedures
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- How the Iran war may affect your money and bills
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Jersey's wellbeing score is below UK and France
- Spots to Go Hang Floating
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Manual for 10 Scrumptious Specialty Mixed drinks
